Treatment of advanced invasive Thymomas in experience of Oncology Department at Regional Centre of Lung Diseases in Poznań and Department of Thoracic Surgery, Poznań University of Medical Sciences
Journal Title: Współczesna Onkologia - Year 2006, Vol 10, Issue 4
Abstract
Introduction: Thymoma is a rare neoplasm, deriving from epithelial tissue of Thymus. ADOC, PAC, PE and VIP are most frequently used combintions. Materials and method: Retrospective analysis including 13 patients treated with chemotherapy between 1995 and 2004. Mean age was 40 years (18-55). Performance status: 8 patients in PS-1 and 5 in PS-2 (ECOG). Histologic types A/AB/B1/B2/B3 – 1/2/1/4/5 respectively and clinical stages: II°/III°/IVA°/IVB° – 2/7/3/1 respectively. Chemotherapy was given as: adjuvant one – 4 cases (3 – III° and 1 – II°), induction treatment in 3 cases (II° and III°), remaining 6 cases due to inoperable disease (2 in III°, 3 in IVA° and 1 in IVB°). Results: In first line following regimens were used: PAC – 2, VIP – 8, ADOC – 3 cases. Radiotherapy was implemented in 8 patients: paliatively: 2 – Superior Vena Cava Syndrome, 1 – bone metastases, radicaly: 1 – adjuvant therapy, 2 – interdisciplinary treatment (induction chemotherapy + surgery + adjuvant radiotherapy), and 2 – combined treatment. In 2 cases ADOC regimen was implemented in second line treatment. Objective response – first line 70% (1 CR and 6PR), second line – 100% (1 PR and 1 CR). Conclusion: Systemic treatment of patients with thymoma leads to achievement of significant response rate. Such treatment can be implemented as an adjuvant one, as an induction therapy and as a part of combination treatment as well as alone one. In case of recurrence it is possible to consider second line treatment and achieve satisfactory clinical improvement and objective response. Massive mediastinum involvement should lead to consideration of prophylactic antithrombotic treatment.
Authors and Affiliations
Rodryg Ramlau, Maciej Bryl, Wojciech Dyszkiewicz, Stanisław Pieluchowski
Keywords
Related Articles
- EP ID EP123559
- DOI -
- Views 60
- Downloads 0
Cancer procoagulant (CP) in surgical oncology diagnostics
A considerable advancement of the neoplastic process at the start of the treatment is one of the major reasons of high mortality caused by malignant neoplasms. Numerous studies have been devoted to the diagnosis of cance...
Czerniak skóry: aktualne możliwości leczenia w Polsce na podstawie analizy leczonych pacjentów i przeglądu literatury
Czerniak należy do najbardziej złośliwych nowotworów człowieka o systematycznie wzrastającym współczynniku zachorowalności. Diagnostyka czerniaka skóry polega na klinicznej ocenie zmian skórnych, a ustalenie dokładnego s...
Postępy w leczeniu przewlekłej białaczki limfocytowej B-komórkowej
Przewlekła białaczka limfocytowa B-komórkowa stanowi ok. 20–30% wszystkich białaczek u dorosłych. W 90% przypadków zachorowania dotyczą osób po 60. roku życia, a mężczyźni chorują 2-krotnie częściej niż kobiety. W osta...
Infantyle haemangiopericytoma - a tumour with high chemosensitivity and favourable prognosis. the Report of the Polish Paediatric Rare Tumours Study
Aim of the study: The analysis of clinical characteristics, course and treatment outcome in children with infantile haemangiopericytoma (HP) registered in the Polish Paediatric Rare Tumours and Polish Paediatric Soft Tis...
Leczenie długotrwale rozwijającego się raka podstawnokomórkowego skóry, niszczącego połowę twarzy – opis przypadku
Rak podstawnokomórkowy (ca basocellulare, basal cell epithelioma, basalioma, ulcus rodens) jest najczęstszym nowotworem skóry. Występuje przede wszystkim u mężczyzn powyżej 40. roku życia narażonych na promieniowanie sł...